This 2017 single-center, open-label phase II trial evaluated the efficacy and safety of weekly intravenous ascorbic acid (AA) in 23 chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC). The dosing regimen included 5 g in week 1, 30 g in week 2, and 60 g weekly from weeks 3 to
This phase II clinical trial evaluated the efficacy and safety of combining arsenic trioxide (ATO) with ascorbic acid (AA) in patients with acute myeloid leukemia (AML) excluding acute promyelocytic leukemia (APL). Eleven patients, including elderly individuals unfit for intensive chemotherapy, received intravenous ATO (0.25 mg/kg/day) and AA (1 g/day) for
This phase II trial evaluated the efficacy and tolerability of long-term once-weekly oral azithromycin (1500 mg) in 16 patients with histologically confirmed MALT lymphoma. Patients received the regimen for up to 6 months, with restaging at 3 and 6 months. The treatment was well tolerated, with mild nausea and diarrhea
